Trending

first-line lung cancer

Roche’s Tecentriq combo extends life in advanced NSCLC

Roche’s Tecentriq combo extends life in advanced NSCLC

Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).

X

Roche’s Tecentriq combo extends life in advanced NSCLC

https://pharmaphorum.com/news/roches-tecentriq-combo-advanced-nsclc/

ASCO 2018 Preview – what to expect from this year’s conference

ASCO 2018 Preview – what to expect from this year’s conference

pharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the

X

ASCO 2018 Preview – what to expect from this year’s conference

https://pharmaphorum.com/views-and-analysis/asco-2018-preview-conference/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com